Moebius Medical

What Moebius Medical does

Moebius Medical is a private, early-stage biotechnology company headquartered in Tel Aviv, Israel, founded in 2008. According to the available firmographic data, the company is developing a new class of mechanical lubricants intended to reduce joint damage, with a therapeutic focus on osteoarthritis — an indication supported by the product-overview note that situates Moebius within the osteoarthritis therapeutics space alongside competitors such as Sun Pharmaceutical's MM-II and Eupraxia Pharmaceuticals' EP-104IAR.

The company operates with a very small team (1-10 employees) and has no disclosed product portfolio, pipeline detail, patents, trademarks, partnerships, or management team in the input data. The company's website (moebiusmedical.com) returned only a loading/verification page at the time of data collection, and no operational announcements, regulatory filings, funding rounds, or strategic transactions were surfaced in the aggregated source material. This data gap precludes characterization of Moebius Medical's specific product mechanism, clinical stage, or development partners.

Given the absence of disclosed revenue, pricing, customers, or GTM motion, no commercial business model can be reliably described. The company should be characterized as a pre-commercial R&D-stage entity whose eventual monetization would most likely flow through out-licensing, partnership with a larger orthopedic / pharma player, or direct commercialization post-regulatory approval. No investors, board composition, or ownership structure were disclosed, leaving the capital base and governance profile unverifiable from the available sources.

Name

Moebius Medical

Website

https://moebiusmedical.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

1–10 employees

Short description

Moebius Medical is a private, Israel-based biotechnology company founded in 2008 that is developing a new class of mechanical lubricants intended to reduce joint damage in osteoarthritis patients. It operates with a small R&D team and remains pre-commercial.

Ownership category

akta.pro rank

Product category

Osteoarthritis Therapeutics (Biotechnology)

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)

Keywords

• Joint lubrication therapy
• Osteoarthritis therapeutics
• Mechanical joint lubricant
• Cartilage protection therapy
• Intra-articular injection

Headquarters

HQ city

Tel Aviv

HQ country

Israel

HQ region

Middle East

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain

Core offering

Moebius Medical is a biotechnology company developing a new class of mechanical lubricants designed to reduce joint damage, with a therapeutic focus on osteoarthritis. The company's offering is an intra-articular, mechanical-lubricant-based therapeutic intended to address cartilage degeneration and joint dysfunction. Specific product candidates, clinical milestones, and commercialization details were not evidenced in the source material reviewed.

Product overview

Moebius Medical is a biotechnology company focused on osteoarthritis therapeutics. Based on the source data reviewed, insufficient information is available to characterize the company's specific product portfolio or service architecture. The company website displays only a loading/verification page, and the provided news sources reference osteoarthritis market trends and competitor products (MM-II from Sun Pharmaceutical Industries, EP-104IAR from Eupraxia Pharmaceuticals) rather than Moebius Medical's own offerings.

Differentiator

Problem solved

Functional benefit

Products and services

• Mechanical joint lubricant for osteoarthritis An intra-articular therapeutic based on a new class of mechanical lubricants designed to reduce joint damage in osteoarthritis, intended for pharmaceutical/biotech licensing partners and ultimately orthopedic and rheumatology prescribers.

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Expansion highlights1 record

Direct peers

• Flexion Therapeutics: Flexion's Zilretta is an extended-release intra-articular corticosteroid for knee osteoarthritis, addressing the same patient population and call point (orthopedists, rheumatologists) as a mechanical lubricant therapy.
• Anika Therapeutics: Anika develops hyaluronic acid-based joint preservation and pain management products (e.g., Monovisc, Orthovisc, Cingal), directly competing in intra-articular osteoarthritis therapies for the same end customers.
• Seikagaku Corporation: Seikagaku is a global leader in hyaluronic acid-based intra-articular injections for osteoarthritis (e.g., Supartz/Artz), making it a directly comparable peer in joint lubrication and viscosupplementation therapeutics.
• Bioventus: Bioventus offers a portfolio of osteoarthritis therapies including intra-articular hyaluronic acid products (Durolane, Gelsyn-3), competing in the same viscosupplementation and joint-health category.
• Eupraxia Pharmaceuticals: Eupraxia is developing EP-104IAR, an intra-articular, extended-release therapy for knee osteoarthritis, directly competing with Moebius's mechanical lubricant approach in the same indication and route of administration.

Emerging players

• Kolon TissueGene: Kolon TissueGene is developing TG-C (Invossa), a cell and gene therapy for knee osteoarthritis, representing an alternative disease-modifying intra-articular approach in the same indication.
• Pacira BioSciences: Pacira is expanding from non-opioid pain into intra-articular and musculoskeletal therapies (e.g., iovera), making it an adjacent emerging competitor in non-systemic joint treatments.

Broad incumbents

• Sun Pharmaceutical Industries: Sun Pharma has referenced MM-II for knee osteoarthritis and operates across specialty therapeutics including rheumatology, providing broad commercial reach that could pressure Moebius's market entry economics.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

• Facebookfacebook.com/RADBioMed
• LinkedInlinkedin.com/company/moebius-medical-ltd-

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Moebius Medical